Single-inhaler triple therapy (ICS/LA BA/LA MA) in asthma management: 2026 update of the Polish expert position statement

Le résumé fourni par la source

This document presents the 2026 update of the expert position statement issued by the Polish Society of Allergology and the Polish Respiratory Society on the use of single-inhaler triple therapy (SITT) in asthma management.It builds upon previous statements and incorporates new evidence from randomized controlled trials, real-world studies, and pharmacoeconomic analyses.The updated recommendations reaffirm and expand the role of SITT in specific clinical scenarios, including patients with small airway disease, those at high risk of exacerbations, and patients with asthma who smoke. Key elements of the Polish approach include the use of SITT with a medium dose of inhaled corticosteroids (ICS) at Step 4B in cases of inadequate response to Step 4A therapy (MART or ICS/LABA with a medium or high dose of ICS), and the use of SITT with a high dose of ICS at Step 5 in the majority of patients before considering biologic therapy.The document emphasizes that treatment selection should reflect the clinical characteristics of asthma and incorporate all available therapeutic and diagnostic options.Avoiding a rigid, algorithmic approach is essential, with therapy tailored to the individual patient.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.